Pandemic flu: Federal preparations for and response to the H1N1 flu outbreak is funded with $7.7 billion in the 2009 supplemental appropriations bill approved by House and Senate conferees June 11. The funds are allotted to HHS, but most - $5.8 billion - will be available only on a contingency basis for critical needs. The remaining $1.85 billion, the amount provided by the original House bill and $350 million more than by the Senate bill, will be immediately available. Bill language has not been released yet, but a House staffer said the money will be divvied up according to earlier House language, which allowed financing of private vaccine production facility construction or rehabilitation (1"The Pink Sheet," May 25, 2009, p. 32). The White House requested the contingency funds June 2; final House and Senate approval on the consensus measure is expected shortly. The agreement came the same day as the World Health Organization announced that the spread of the H1N1 virus meets criteria for an influenza pandemic
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.
With European biosimilars developers buoyed by recent regulatory moves, Medicines for Europe’s Isabell Remus and Julie Maréchal-Jamil discuss the next steps forward for the industry.
